NEW YORK (GenomeWeb News) – SuperGen said today that it will screen epigenetic targets for cancer drugs for GlaxoSmithKline, under an agreement announced today.

The Dublin, Calif.-based drug screening and development firm said that it will receive $5 million up front, which includes a $3 million investment from the UK drug maker. It also said that milestone and royalty payments from GSK for development and commercialization could potentially surpass $375 million, and it could also receive tiered royalties reaching double-digits on products derived from the collaboration.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.